Japan
bitBiome, Inc., founded in 2018, is a cutting-edge player in the synthetic biology sector. The company boasts a proprietary microbial single-cell microfluidic sequencing technology called bit-MAP. Central to their innovation is the bit-GEM database, a repository of over 2 billion microbial sequences, expanding at an impressive rate of nearly 1 billion per year. This comprehensive database leverages sequences from varied sources, with a significant portion sourced from environmental samples like soil and seawater.
What distinguishes bitBiome from competitors is bit-QED, their unique enzyme discovery and development platform. It integrates bioinformatics, protein structure analysis, and machine learning to offer an end-to-end solution that includes services from single cell genomics to directed evolution campaigns. Primarily driving innovation in the chemical, food and nutrition, and life sciences industries, bitBiome is positioned to unlock the full potential of microbial applications. Investors will find its steady expansion and robust R&D focus particularly compelling.
